A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Phase 1
150
about 2.5 years
18+
5 sites in AZ, MI, NC +2
What this study is about
This trial is testing a new treatment called SON-DP in people with advanced or metastatic solid tumors that have returned after other treatments. The goal is to see if this treatment is safe and how it works in the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take SON-DP
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: MTD (Maximum tolerable dose) / RP2D (Recommended dose for phase II), Number of participants with AEs, with abnormal vital signs, abnormal ECG readings, abnormal clinical laboratory tests results, abnormal physical examinations and abnormal ECOG performance status.
Secondary: Cmax, DCR, DOR, ORR, OS, PFS, T1/2, TTP
Oncology